 Global Blood Therapeutics Inc NASDAQ: GBT reported a Q1 EPS loss of 1.21 wider than the anticipated loss estimate of 1.01. Q1 sales of 39.04 million well below the consensus of 43.00 million, all of which stemmed from sickle-cell disease drug, Oxbryta. 